Docking Studies on Some Benzimidazole and Triazole Analogues as Antihypertensive Agents

Authors

  • Deepti Mishra Sri Aurobindo Institute of Pharmacy Indore M.P (India).
  • Vengurlekar Sudha Sri Aurobindo Institute of Pharmacy Indore M.P (India)
  • Chaturvedi S C Sri Aurobindo Institute of Pharmacy Indore M.P (India).

DOI:

https://doi.org/10.37591/(rrjobi).v5i2.221

Keywords:

Hypertension, Antihypertensive agents, docking studies

Abstract

The incidence rate of hypertension continues a phenomenal rise and so, there is a growing need to identify novel therapeutic agents with improved efficacy and reduced side effects. In these circumstances, drugs acting on multiple targets could offer superior efficacy profiles compared with single target drugs. Some molecules have been designed using rational drug design approach and evaluated by performing docking studies. Targets used were an angiotensin-converting enzyme, angiotensin receptor, aldosterone receptor, rennin enzyme, beta receptors (b1/b2). Surflex-docking studies were performed on a series of substituted benzimidazole fused triazole ring as an antihypertensive activity. Docking studies revealed that the nitro group, fluoro group on benzimidazole, and nitro group of triazole were significant for binding to all receptors, and some essential substituted group were also identified. Designed compounds were found to have a binding affinity with multiple targets.

 

Keywords: Antihypertensive agents, benzimidazole, docking studies, triazole

Cite this Article

Mishra Deepti, Vengurlekar Sudha, Chaturvedi S.C. Docking Studies on Some Benzimidazole and Triazole Analogues as Antihypertensive Agents. Research & Reviews: A Journal of Bioinformatics. 2018; 5(2): 37–39p.

Downloads

Published

2018-10-08

Issue

Vol. 5 No. 2 (2018)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.